Organigram

A separate executive board, a separate supervisory body (“Board of Directors”), and a Scientific Advisory Board (SAB) collectively ensure the BIH’s autonomy. Changes are also taking place in relation to the Charité’s already established management and supervisory bodies: The federal government will have a seat on the Charité’s supervisory board, and the BIH’s Scientific Director will have a seat on the Charité’s executive board. The Charité’s executive board consists of a total of six members.

Organigramm und Governancestruktur

Board of Directors

The BIH is managed by a board of directors. In accordance with legal requirements, it is responsible for all financial, personnel, and structural decisions concerning the BIH.

Board Members

  • Prof. Dr. Christopher Baum

    Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin

  • [Translate to englisch:]

    Dr. Doris Meder

    Administrative Director of the BIH at Charité

Professor Christopher Baum is the Chairman of the Board of Directors of the BIH. More information about Professor Baum can be found in his curriculum vitae.

Extended Board of Directors

In order to include the full-time scientific staff of the translational research area in the opinion-forming and decision-making of the directorate, an extended board of directors is formed. The extended board of directors advises the voting members of the board of directors with regard to its tasks. For this purpose, it may submit statements to the voting members and request information as well as the treatment of its motions.

The Extended Board of Directors consists of:

  • Professor Joachim Spranger (Dean)
  • four elected persons belonging to the full-time scientific staff of the Translational Research Unit.

Speaker

Prof. Dr. Birgit Sawitzki
Professor for Translational Immunology, BIH

Vice Speaker

Prof. Dr. Il-Kang Na
BIH Johanna Quandt Professor for Therapy-induced Re-Modelling in Immuno-Oncology, BIH

Governing Board

All activities of BIH are supervised by the Supervisory Board, which is also responsible for approving essential decisions such as the business plan, strategic planning, appointments, and investments.

Deputies of the German Government
Deputies of the German Government  
MinDir’in Prof. Dr. Veronika von Messling Head of the Department of Health and Life Sciences, Federal Ministry of Research, Technology, and Space; Chair of the Governing Board
Deputies of the federal state of Berlin
Deputies of the federal state of Berlin  
State Secretary Dr. Henry Marx State Secretary, Senate Department for Science, Health, and Long-Term Care; Vice Chair of the Governing Board
External experts
External experts  
Prof. Dr. Martin Hirsch Director of the Institute for Artificial Intelligence in Medicine, Philipps University of Marburg
Prof. Dr. Blanche Schwappach-Pignataro Dean, Medical Center Hamburg-Eppendorf (UKE)
Dr. Joachim Kreuzburg Manager and Consultant, Former CEO of Sartorius AG
Prof. Dr. Gabriele Gillessen-Kaesbach Professor, University of Lübeck

Scientific Advisory Board

The Scientific Advisory Board is responsible for providing the Executive Board and Supervisory Board with external specialized knowledge regarding future important research topics and ongoing scientific and strategic issues; it meets every six months. At present the Scientific Advisory Board consists of thirteen international experts in translational research and systems medicine.

Chair of the Scientific Advisory Board

Prof. Jens Rittscher
Nuffield Department of Medicine, University of Oxford, UK

Members of the Scientific Advisory Board
Name Institution
Prof. Lina Badimon Universitat Central de Catalunya, Spanien
Trine Bartholdy Chief Business Officer, BioInnovation Institute Denmark
Prof. Segun Fatumo Queen Mary University of London; MRC Uganda/London School of Hygiene and Tropical Medicine, UK
Prof. Teri Manolio National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Prof. David Moher Ottawa Hospital Research Institute, Canada
Prof. Jens Rittscher Nuffield Department of Medicine, University of Oxford, UK
Prof. André Terzic Mayo Clinic, USA
Prof. Emily Sena Centre for Clinical Brain Sciences, The University of Edinburgh, Scotland
Prof. David A. Williams Division of Hematology/Oncology, Boston Children’s Hospital / Harvard Medical School, USA
Prof. Eleftheria Zeggini Helmholtz Zentrum München, Germany

Legal texts